Acción MGRX MANGOCEUTICALS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Mangoceuticals, Inc.

Acciones

MGRX

US56270V1061

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:00:00 06/06/2024 		Varia. Cinco días. Varia. 1 de enero.
0,382 USD -3,66 % Gráfico intradía de Mangoceuticals, Inc. -7,95 % +37,96 %
06/06 Aprobada la patente de Mangoceuticals para cuidados preventivos en Australia MT
06/06 Mangoceuticals, Inc. Recibe una Notificación de Aceptación de la Solicitud de Patente en Australia para la Tecnología de Cuidados Preventivos y Enfermedades Respiratorias CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Mangoceuticals Patent Approved for Preventive Care in Australia
MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
Mangoceuticals, Inc. Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies
MangoRx to Introduce “MOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances
Mangorx to Introduce ?Mojo? Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances
Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets
MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts
Sector Update: Health Care Stocks Advance Late Afternoon
Sector Update: Health Care
Top Midday Gainers
MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications
Mangoceuticals, Inc. to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications
MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration
Mangoceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement
Mangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive Care
Mangoceuticals Signs Securities Purchase Deal; Mexican Unit Enters Technical Deal With Emifarma
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products
Mangoceuticals, Inc. announced that it expects to receive CAD 1.5 million in funding from Platinum Point Capital LLC
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción MGRX
  4. Noticias Mangoceuticals, Inc.
  5. Otros idiomas